• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 30, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Insilico Medicine announces novel 3CL protease inhibitor preclinical candidate for COVID-19 treatment

Bioengineer by Bioengineer
May 24, 2022
in Chemistry
Reading Time: 3 mins read
0
covid image
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

NEW YORK, May 24, 2022 — Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.

covid image

Credit: Insilico

NEW YORK, May 24, 2022 — Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.

Insilico’s PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico’s AI platform. The compound can be efficiently prepared with a two-step synthesis from commercial starting materials. In preclinical studies, it demonstrated a favorable profile with good in vivo efficacy at low doses and its observed efficacy is independent of co-administration with CYP3A4/Pgp inhibitor (e.g. Ritonavir). It also showed broad-spectrum antiviral activities, not only for SARS-CoV-2 and its variants, but also for other types of coronaviruses that cause diseases including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).

“This molecule designed by AI has distinct pharmacophores from existing 3CL protease inhibitors and binds to the target protein in a unique, irreversible, covalent binding mode as demonstrated by a co-crystal structure,” said Feng Ren, Ph.D., Chief Scientific Officer of Insilico Medicine. “We are committed to progress the molecule as fast as possible into clinical trials evaluating its usage in COVID-19 treatment.”

Insilico initially trained its end-to-end AI platform to combat the pandemic early in the outbreak based on knowledge of the virus’ structure and properties developed from the SARS outbreak in 2003. Empowered by its AI platform, the company narrowed and identified the 3CL target in early 2020 and then published its first set of novel compound structures designed using its small molecule generation platform Chemistry42 in February 2020.

 “The COVID-19 pandemic brought global attention to the pressing need for rapid drug development,” said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine. “We made an executive decision to start our COVID-19 program early. We were mobilized along with the rest of the scientific community and were able to demonstrate how powerful AI tools can be in the fight against the disease.”

The epidemic caused by the Novel Coronavirus has had a significant impact on human health and economic development and has brought severe challenges to global public health security. Insilico’s R&D team has initiated investigational new drug (IND)-enabling studies for the PCC to accelerate its progression to a clinical asset.

Since 2021, Insilico has nominated 7 preclinical candidates discovered and designed using its AI platform in a variety of disease areas, including fibrosis, inflammation, and cancer. It also successfully completed a Phase 0 microdose trial and entered a Phase I clinical trial with its first internally developed program for fibrosis.

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.

For more information, visit www.insilico.com.

For media inquiries, please contact [email protected].



Share12Tweet8Share2ShareShareShare2

Related Posts

Mapping Proteome-wide Selectivity of Diverse Electrophiles

Mapping Proteome-wide Selectivity of Diverse Electrophiles

October 30, 2025
blank

Tufts Physicists Shed Light on the Origins of Matter

October 30, 2025

Observing a Black Hole Flicker Across Time

October 30, 2025

When Electrons Harmonize and Perceive Their Surroundings

October 30, 2025

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1292 shares
    Share 516 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    202 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    136 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

PhET Interactive Simulations Honored with Meggers Project Award

Survival Insights for 2021 WHO Glioma Patients

PFAS Levels Linked in Water and Southern California Adults

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.